T1	Participants 628 660	children and adolescents with CF
T2	Participants 744 920	44 CF patients (aged 7-19 y; 20 males) who were randomly assigned to receive magnesium (n = 22; 300 mg/d) or placebo (n = 22) for 8 wk with a 4-wk washout period between trials
T3	Participants 922 979	All patients were undergoing conventional treatment of CF
